Ignite Creation Date:
2024-05-06 @ 8:16 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02706691
Status:
TERMINATED
Last Update Posted:
2019-04-16
First Post:
2016-03-01
Brief Title:
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
Phase IIa Study of the Efficacy of Single Agent BGJ398 Infigratinib in FGFR1-3 Translocated Mutated or Amplified Squamous Cell Carcinoma of the Head and Neck
Status:
TERMINATED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study stopped due to poor enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase IIa trial studies how well the experimental drug BGJ398 infigratinib works in treating patients with fibroblast growth factor receptor FGFR 1-3 translocated mutated or amplified head and neck cancer that has returned after a period of improvement BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2016-01121 | REGISTRY | CTRP Clinical Trial Reporting Program | None |